Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.

Weight-loss drugs like semaglutide and tirzepatide may help shrink waistlines, but new research shows they fail to boost ...

Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.

GLP-1 drugs like semaglutide (Ozempic) and tirzepatide (Mounjaro) may shrink fat, but also crucial muscle mass, with little ...

The review that pooled the results of 11 studies has found that people started regaining weight two months after stopping the ...

While many believe the agents to be potential game changers, evidence is still lacking in psoriatic disease, and experts urge ...

Patients put on weight loss drugs like Ozempic and Wegovy may start regaining weight within weeks of discontinuing them, a ...

GLP-1RA users had a 37% lower risk of developing dementia compared to those on other antidiabetic drugs. Stroke risk reduced ...

For adults with type 2 diabetes and obesity, glucagon-like peptide 1 receptor agonists (GLP-1 RAs) are associated with a lower risk for dementia, stroke, and all-cause mortality compared with other ...

Explore how semaglutide and tirzepatide may protect against dementia and stroke—keep reading for clinical implications and evidence.

Adults with obesity were more likely to achieve a 10% or greater weight loss at 1 year if they continued using their ...